Thanks to these antibodies, the number of people who need to undergo genetic analysis can be reduced, i.e., in patients who do not have antibodies to IFN-ω and IFN-α2, the diagnosis of APS-1 can be ruled out without testing for the AIRE gene. This evidence concerns the gene AIRE and Autoimmune polyendocrinopathy type 1.